



March 12<sup>th</sup>, 2021  
Biocomo, Inc.

New patent application for Coronavirus (SARS-CoV-2) Vaccine  
using BC-PIV vector has been filed

Biocomo, Inc. today announced that Biocomo, Mie University and the University of Tokyo have confirmed that Biocomo's new coronavirus (SARS-CoV-2) vaccine using BC-PIV vector demonstrated extremely high vaccine efficacy and have jointly filed a patent application out of this new research outcome on February 25, 2021.

Contact: [ifno@biocomo.jp](mailto:ifno@biocomo.jp)

Masayuki Fukumura, Representative Director, Biocomo, Inc.